MMP-9[Biotin], His & Avi, Human
MMP-9[Biotin], His & Avi, Human

Immobilized Anti-MMP-9 Antibody, hFc Tag at 1μg/ml (100μl/well) on the plate. Dose response curve for MMP-9[Biotin], His & Avi, Human, His Tag with the EC50 of 31.0ng/ml determined by ELISA.

MMP-9[Biotin], His & Avi, Human

The purity of MMP-9[Biotin], His & Avi, Human is greater than 95% as determined by SEC-HPLC.

MMP-9[Biotin], His & Avi, Human

MMP-9[Biotin], His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

MMP-9[Biotin], His & Avi, Human

Matrix metalloproteinase 9 (MMP9) contributes to this process and deficiencies in the MMP9 lead to impaired healing. Inappropriate expression of MMP9 also contributes to impaired re-epithelialization. Previously we demonstrated that FOXO1 was activated in wound healing but to higher levels in diabetic wounds. To address mechanisms of impaired re-epithelialization we examined MMP9 expression in vivo in full thickness dermal scalp wounds created in experimental K14.
Z04561
¥123,118.00

Ask us a question
Product Introduction
Species Human
Protein Construction
MMP-9 (Ala20-Asp707)
Accession # P14780		 His Avi
N-term C-term
Conjugate Biotin
Purity > 95% as determined by Bis­Tris PAGE 
> 95% as determined by HPLC
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Immobilized Anti­MMP­9 Antibody, hFc Tag at 1μg/ml (100μl/well) on the plate can bind MMP-9[Biotin], His & Avi, Human. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 79.3 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 95-105 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Examples
  • MMP-9[Biotin], His & Avi, Human
    • MMP-9[Biotin], His & Avi, Human

    Immobilized Anti-MMP-9 Antibody, hFc Tag at 1μg/ml (100μl/well) on the plate. Dose response curve for MMP-9[Biotin], His & Avi, Human, His Tag with the EC50 of 31.0ng/ml determined by ELISA.

  • MMP-9[Biotin], His & Avi, Human
    • MMP-9[Biotin], His & Avi, Human

    The purity of MMP-9[Biotin], His & Avi, Human is greater than 95% as determined by SEC-HPLC.

  • MMP-9[Biotin], His & Avi, Human
    • MMP-9[Biotin], His & Avi, Human

    MMP-9[Biotin], His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background Matrix metalloproteinase 9 (MMP9) contributes to this process and deficiencies in the MMP9 lead to impaired healing. Inappropriate expression of MMP9 also contributes to impaired re-epithelialization. Previously we demonstrated that FOXO1 was activated in wound healing but to higher levels in diabetic wounds. To address mechanisms of impaired re-epithelialization we examined MMP9 expression in vivo in full thickness dermal scalp wounds created in experimental K14.
Synonyms MMP-9; GELB; CLG4B; MANDP2; Gelatinase B

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.